https://ipharmag.com/article/wtc-9-11-cancer-cases-25-years iPharmag en 2026-09-11T13:28:40+00:00 Twenty-Five Years After 9/11, Cancer Cases Among Survivors Keep Rising https://ipharmag.com/article/ucla-cord-blood-alloeso-t-cells-cancer iPharmag en 2026-09-11T13:28:40+00:00 Scientists Turn Donated Cord Blood Into an ‘Off-the-Shelf’ Cancer Cell Therapy https://ipharmag.com/article/time-restricted-eating-type-1-diabetes iPharmag en 2026-09-11T13:28:40+00:00 An 8-Hour Eating Window Improved Blood Sugar in Type 1 Diabetes — Safely, Small Study Finds https://ipharmag.com/article/fda-bayer-sevabertinib-hyrnuo-her2-lung-cancer-first-line iPharmag en 2026-09-11T13:28:40+00:00 FDA Clears Bayer’s Hyrnuo as a First-Line Option for HER2-Mutated Lung Cancer https://ipharmag.com/article/encoded-therapeutics-275m-dravet-gene-therapy iPharmag en 2026-09-11T13:28:40+00:00 Encoded Raises $275M to Push a One-Time Gene Therapy for a Severe Childhood Epilepsy https://ipharmag.com/article/solstice-oncology-225m-ctla4-porustobart iPharmag en 2026-09-09T23:20:29+00:00 Solstice Launches With $225M and a Faster-Clearing Take on an Old Cancer Target https://ipharmag.com/article/sandhoff-disease-gene-therapy-cat-model-lifespan iPharmag en 2026-09-09T23:20:29+00:00 A One-Time Gene Therapy Tripled Lifespan in a Fatal Childhood Disease Model https://ipharmag.com/article/h-pylori-colorectal-cancer-evidence iPharmag en 2026-09-09T23:20:29+00:00 Does a Common Stomach Bug Raise Colon Cancer Risk? The Evidence Is Building — and Messy https://ipharmag.com/article/astrazeneca-tozorakimab-il33-copd-mucus-plugs iPharmag en 2026-09-09T23:20:29+00:00 AstraZeneca Drug Becomes First Biologic to Cut COPD ‘Mucus Plugs,’ Data Show https://ipharmag.com/article/arpa-h-advocate-ai-heart-failure-62m iPharmag en 2026-09-09T23:20:29+00:00 US Health Agency Bets $62M on FDA-Authorized AI That Would Treat Heart Failure